Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:56 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride Binding
NCT00562198 · Orion Corporation, Orion Pharma · PHASE2 · terminated · last registry update 2008-06-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Illogistical results found in interim evaluation.” | – | Registry record, Orion Corporation, Orion Pharma |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DRD3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2009-04-07Phase 3 first posted: Charite University, Berlin, Germany, Olanzapine (NCT00876772)
- 2009-03-13Results posted on the registry: Pfizer's Upjohn has merged with Mylan to form Viatris Inc., ziprasidone hydrochloride + olanzapine (NCT00329108)
- 2008-12-10Phase 3 first posted: Pfizer's Upjohn has merged with Mylan to form Viatris Inc., placebo and pregabalin + pramipexol (NCT00806026)
- 2008-07-29Phase 3 first posted: Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Intramuscular ziprasidone mesylate + Intramuscular haloperidol (NCT00723606)
- 2007-12-06Phase 3 first posted: Charite University, Berlin, Germany, Olanzapine (NCT00568672)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision